Treatment-refractory ALK-positive inflammatory myofibroblastic tumour of the oral cavity

LaVigne, Anna W.; Meredith, David M.; D’Adamo, David R.; Margalit, Danielle N.

doi:10.1136/bcr-2017-221553

Cited by 6 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multinodular intraabdominal tumors are prone to the highest recurrence rate, as well as IMTs that are surgically challenging anatomical locations such as the head and neck region where complete surgical resection can pose great difficulty for a surgeon. Statistically, en-bloc excision with clear margins (R0) of a single IMT has a very low recurrence rate [27,61,33,[161][162][163][164]. Several studies advocate for re-excision of local recurrence as a treatment of choice, with little evidence available for optimal therapy for inoperable, relapsed, or metastatic IMT [11,162].…”

Section: Surgical Treatmentmentioning

confidence: 99%

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

CHMIEL,

SłOWIKOWSKA,

BANASZEK

et al. 2024

View full text Add to dashboard Cite

Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult to define. Targeted therapies are crucial for achieving sustained response to treatment within the context of genetic alteration in IMT. Crizotinib, an ALK tyrosine kinase inhibitor (TKI), was officially approved by the US Food and Drug Administration (FDA) in 2020 to treat IMT with ALK rearrangement. However, most patients face resistance and disease progression, requiring consideration of sequential treatments. Combining radiotherapy with targeted therapy appears to be beneficial in this indication. Early promising results have also been achieved with immunotherapy, indicating potential for combined therapy approaches. However, defined recommendations are still lacking. This review analyzes the available research on IMT, including genetic disorders and their impact on the course of the disease, data on the latest targeted therapy regimens and the possibility of developing immunotherapy in this indication, as well as summarizing general knowledge about prognostic and predictive factors, also in terms of resistance to systemic therapy.

show abstract

Section: Surgical Treatmentmentioning

confidence: 99%

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

CHMIEL,

SłOWIKOWSKA,

BANASZEK

et al. 2024

View full text Add to dashboard Cite

show abstract

“…Systemic symptoms and laboratory abnormalities described in up to 30% of IMTs overall [75] are not typically reported in sinonasal or laryngeal IMTs [76,77]. Laryngeal IMTs generally arise in the glottis and follow a benign clinical course following excision [77,78], while sinonasal and oral cavity IMTs are clinically more aggressive, with higher rates of recurrence, metastasis and mortality despite treatment [79,80]. Other reported sites include pharynx, neck, skull base, salivary glands, trachea, and orbit [74,79].…”

Section: Inflammatory Myofibroblastic Tumormentioning

confidence: 99%

Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck

Baranov

Hornick

2020

Head and Neck Pathol

View full text Add to dashboard Cite

Fibroblastic and myofibroblastic neoplasms of the head and neck encompass a group of rare tumor types with often overlapping clinicopathologic features that range in biologic potential from benign to overtly malignant. Even neoplasms with no metastatic potential may provide significant therapeutic challenges in this region due to the unique anatomy of the head and neck. This review will cover the following entities, highlighting important clinical aspects of each neoplasm and then focusing on their characteristic histomorphology, immunophenotype, and molecular alterations: nodular and cranial fasciitis, fibrous hamartoma of infancy, nasopharyngeal angiofibroma, nuchal-type and Gardner fibromas, desmoid fibromatosis, dermatofibrosarcoma protuberans and giant cell fibroblastoma, solitary fibrous tumor, inflammatory myofibroblastic tumor, low-grade myofibroblastic sarcoma, infantile fibrosarcoma, low-grade fibromyxoid sarcoma, and sclerosing epithelioid fibrosarcoma. While some of these neoplasms characteristically arise in the head and neck, others are rarely described in this anatomic region and may therefore be particularly difficult to recognize. Distinction between these entities, however, is crucial, particularly as the molecular pathogenetic basis for these neoplasms are being rapidly elucidated, in some instances allowing for targeted therapeutic approaches.

show abstract

Unusual Presentation of Tonsillar Spindle Cell Neoplasm: A Case Report

Babu

Sahni

Lakhera

et al. 2023

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Treatment-refractory ALK-positive inflammatory myofibroblastic tumour of the oral cavity

Cited by 6 publications

References 21 publications

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

Soft Tissue Special Issue: Fibroblastic and Myofibroblastic Neoplasms of the Head and Neck

Unusual Presentation of Tonsillar Spindle Cell Neoplasm: A Case Report

Contact Info

Product

Resources

About